[Research on the negative immune regulation of NK cells in patients with primary immune thrombocytopenia]

Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):399-403. doi: 10.3760/cma.j.issn.0253-2727.2017.05.009.
[Article in Chinese]

Abstract

Objective: To investigate the levels of NK cells and their relevant cytokines (IL-10, TGF-β and IFN-γ) in patients with primary immune thrombocytopenia (ITP) . Methods: All samples were obtained from 42 patients (22 newly diagnosed and 20 in remission) and 20 healthy volunteers. The levels of IL-10 and IFN-γ in blood serum were detected by enzyme-linked immunosorbent assay (ELISA) . The percentage of CD3(-) CD56(+) NK cell, CD3(-) CD56(bright) CD16(-) NK cell, CD3(-) CD56(dim) CD16(+) NK cell in peripheral blood lymphocyte were detected by flow cytometry. The NK cells were isolated by immunomagnetic microbeads. The mRNA expression levels of IL-10, TGF-β, and IFN-γ in NK cells were detected by real-time fluorescent quantitative PCR. Correlation between the above measured results was analyzed. Results: ① The blood serum level of IFN-γ in newly diagnosed ITP patients [ (653.0±221.6) ng/L] was higher than that in remission ITP patients [ (484.4±219.5) ng/L] and healthy control [ (390.9±253.5) ng/L] (P=0.022, P=0.001) . The blood serum level of IL-10 in newly diagnosed ITP patients was lower than that in healthy control [ (52.09±26.66) ng/L vs (79.44±38.43) ng/L, P=0.007]. ②The percentage of NK cell in newly diagnosed and remission ITP patients [ (9.53±3.93) %, (9.03±3.78) %] were significantly lower than that in healthy control [ (13.72±7.42) %] (P=0.013, P=0.007) . The ratio of CD3(-) CD56(bright) CD16(-) NK cell/total NK cells in newly diagnosed ITP patients was higher than that in healthy control [ (6.85±4.43) % vs (4.05±2.81) %, P=0.032]. The ratio of CD3(-)CD56(dim) CD16(-) NK cell/total NK cells in newly diagnosed ITP patients was lower than that in healthy control [ (93.14±4.43) % vs (95.94±2.81) %, P=0.032]. ③ There was no significant difference in the mRNA expression level of IFN-γ in NK cells of ITP patients and healthy control (all P>0.05) . The mRNA expression levels of IL-10 and TGF-β in NK cells in newly diagnosed ITP patients were significantly higher than that in healthy control (1.82±1.32 vs 1.02±1.03, P=0.023; 2.80±2.31 vs 1.46±1.37, P=0.028) . The ratio of CD3(-)CD56(bright) CD16(-) NK cell/total NK cells was positively correlated with the mRNA expression levels of IL-10, TGF-β in NK cells (r=0.424, P=0.001; r=0.432, P<0.001) . Conclusion: NK cells may compensate for the deficiency of the number by enhancing the secretion of negative regulation cytokines, acting as "protective" roles in the disease.

目的: 探讨原发免疫性血小板减少症(ITP)患者外周血中NK细胞及其相关细胞因子IFN-γ、IL-10、TGF-β的变化。 方法: 以22例初诊ITP患者(初诊组)、20例治疗后完全缓解ITP患者(完全缓解组)为研究对象,以20名健康志愿者为对照组。采用ELISA法检测三组受试者血清IFN-γ及IL-10水平;用流式细胞术检测NK细胞(CD3(-)CD56(+))及其Bright亚群(CD3(-)CD56(bright) CD16(-))、Dim亚群(CD3(-)CD56(dim) CD16(+))水平;采用免疫磁珠法分离NK细胞,实时荧光定量PCR检测IFN-γ、IL-10、TGF-β基因mRNA的表达,并将以上测得结果做相关性分析。 结果: ①初诊组ITP患者血清IFN-γ浓度[(653.0±221.6)ng/L]高于完全缓解组[(484.4±219.5)ng/L]和对照组[(390.9±253.5)ng/L](P值分别为0.022、0.001),血清IL-10浓度低于对照组[(52.09±26.66)ng/L对(79.44±38.43)ng/L,P=0.007]。②初诊组、完全缓解组患者外周血NK细胞比例[(9.53±3.93)%、(9.03±3.78)%]均低于对照组[(13.72±7.42)%](P=0.013,P=0.007);初诊患者外周血Bright亚群占NK细胞的比例高于对照组[(6.85±4.43)%对(4.05±2.81)%,P=0.032];初诊组外周血Dim亚群占NK细胞的比例低于对照组[(93.14±4.43)%对(95.94±2.81)%,P=0.032]。③初诊组、完全缓解组及对照组NK细胞IFN-γ基因mRNA表达差异无统计学意义(P>0.05),初诊组NK细胞IL-10、TGF-β基因mRNA表达高于对照组(1.82±1.32对1.02±1.03,P=0.023;2.80±2.31对1.46±1.37,P=0.028)。外周血Bright细胞占NK细胞的比例与NK细胞IL-10及TGF-β基因mRNA表达呈正相关(r=0.424,P=0.001;r=0.432,P<0.001)。 结论: NK细胞可能通过加强分泌免疫负调控因子来代偿其数量的不足,在疾病中起保护作用。.

Keywords: Interferon-gamma; Interleukin-10; Killer Cell, natural; Thrombocytopenia; Transforming growth factor beta.

MeSH terms

  • CD56 Antigen
  • Flow Cytometry
  • Humans
  • Interleukin-10
  • Killer Cells, Natural*
  • Purpura, Thrombocytopenic, Idiopathic*

Substances

  • CD56 Antigen
  • IL10 protein, human
  • Interleukin-10

Grants and funding

基金项目:国家自然科学基金(81170472、81370607、81400085、81400088);天津市自然科学基金重点项目(12JCZDJC21500);天津市抗癌重大专项攻关计划(12ZCDZSYl79000、12ZCDZSYl8000)